A systematic review examined pre-clinical studies on how cannabidiol (CBD) affects cancer cells in dogs. The research focused on lymphoma, mammary cancer, glioma, prostate cancer, osteosarcoma, and urothelial carcinoma. These studies were mostly based on cellular models rather than living animals or people. The review found that CBD exerts antiproliferative and proapoptotic effects, meaning it can slow cancer cell growth and encourage cell death. It also modulates intracellular signaling pathways like ERK, JNK, and caspases. Additionally, the review noted that CBD can have synergistic or antagonistic effects when combined with other drugs. Safety data indicated that CBD was safe and well-tolerated in these pre-clinical settings. However, the review highlighted that fewer publications are available for dogs compared to humans. There was also no comprehensive review of findings performed prior to this study. The authors noted a need to better elucidate mechanisms and standardize concentrations and formulations. Readers should understand that these findings highlight potential uses but do not prove effectiveness in real-world dog patients yet.
Systematic review of preclinical CBD effects in canine cancersLab tests suggest CBD may help treat cancer in dogs
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Consider the preclinical evidence for CBD in canine cancers as preliminary and requiring further mechanistic and formulation studies.
This is a systematic review of preclinical studies examining cannabidiol (CBD) for various canine cancers, including lymphoma, mammary cancer, glioma, prostate cancer, osteosarcoma, and urothelial carcinoma. The authors synthesized evidence that CBD exerts antiproliferative and proapoptotic effects and modulates intracellular signaling pathways, including ERK, JNK, and caspases. They also noted that CBD can have synergistic and antagonistic effects when combined with other drugs.
The review highlights significant limitations. The evidence is based on pre-clinical studies, mostly cellular models, with fewer publications available compared to human studies. No comprehensive review of these findings was performed prior to this study. The authors note a need to better elucidate mechanisms and to standardize concentrations and formulations.
Safety data were not reported, but the authors state that CBD was safe and well-tolerated in dogs. The practice relevance is restrained, with the authors supporting potential clinical use based on safety and tolerability in dogs. However, they caution against overstating potential clinical use or positioning CBD as an anticancer agent across different cancer types. The findings highlight potential associations, but causation is not explicitly distinguished.
What this means for you:
Lab tests show CBD may help treat cancer in dogs, but human use is not yet proven. More on Cancer
Targeted cytokine delivery platforms in canine oncology provide data for human immuno-oncology dose selection
Cytokine Therapies Show Potential for Treating Canine Cancers
This mini review synthesizes evidence on targeted cytokine delivery platforms, such as IL-12 and IFN-beta, in dogs with various spontaneous …
New research explores how targeted cytokine delivery systems can treat various cancers in dogs and provide data for future human cancer trea…
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…
Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors
Cancer Patients Live Longer When Immunotherapy Starts Early in Day
This systematic review and meta-analysis evaluated 6129 patients with advanced solid tumors receiving immune checkpoint inhibitors. Earlier …
• Morning immunotherapy shots link to longer survival for advanced cancers • Helps patients fighting lung stomach kidney and other tough can…
High tumour mutation burden improves overall survival in solid tumours treated with immune checkpoint inhibitors
High Mutation Counts May Predict Better Cancer Survival Outcomes
This systematic review and meta-analysis evaluated 5278 patients with solid tumours treated with immune checkpoint inhibitors or chemotherap…
High mutation counts in tumors may help predict who will survive longer when taking powerful immune-boosting cancer drugs
View Original Abstract ↓
Preparations of Cannabis sativa have been used for medicinal purposes for many centuries Currently, it is known that the phytocannabinoids present in the Cannabis sativa plant can modulate the endocannabinoid system, producing a variety of effects. Among the most abundant phytocannabinoids are delta-9-tetrahydrocannabinol (19-THC) and cannabidiol (CBD). CBD lacks psychotropic properties and has been shown to inhibit cell proliferation and migration, while inducing apoptosis in various human tumor cells. Studies evaluating CBD in dogs are more recent than those in humans, and to date, fewer publications are available. However, CBD has been shown to be safe and well-tolerated in dogs, supporting its potential clinical use. Since approximately 2015, some studies have been conducted evaluating CBD in different types of canine cancer; however, no comprehensive review of these findings has been performed.
we conducted a systematic review Following the PRISMA 2020 guidelines.to compile the existing evidence on the anticancer effects of CBD in dogs.
We found that the studies conducted so far are pre-clinical, mostly based on cellular models, and that available data are primarily in lymphoma, mammary cancer, glioma, prostate cancer, osteosarcoma, and urothelial carcinoma. These studies consistently show that CBD exerts antiproliferative and proapoptotic effects, in some cases by modulating intracellular signaling pathways, including ERK, JNK, and caspases. Additionally, some studies have evaluated the combination of CBD with other drugs, reporting both synergistic and antagonistic effects. Overall, these findings highlight the potential of CBD as an anticancer agent across different cancer types.
Further studies are required to better elucidate the mechanisms underlying the effects of CBD and to standardize concentrations and formulations, enabling reliable, comparable results and the development of clinical studies evaluating the role of CBD in canine oncology.
Meta-analysis finds systemic lupus erythematosus elevates coronary artery disease risk
People with lupus face higher heart disease risk but genetics show no direct link
Related in Cardiology
Early aortic valve intervention significantly reduces MACE compared to clinical surveillance in asymptomatic severe aortic stenosis
Early valve surgery reduces major heart events for aortic stenosis
This systematic review and meta-analysis of 3,086 patients found that early aortic valve intervention (AVR) results in a significant reducti…
New data shows that early surgical intervention can significantly reduce major heart complications for people with severe aortic stenosis.
Vagal nerve stimulation did not meet the primary endpoint of reduced cardiovascular death or HF hospitalization
Trial shows vagal nerve stimulation for heart failure patients
This randomized controlled trial evaluated vagal nerve stimulation (VNS) in 532 patients with heart failure and reduced ejection fraction. T…
A new trial explores if stimulating a specific nerve can help people living with heart failure manage their symptoms and stay out of the hos…
ICM-guided congestion management shows no difference in arrhythmia occurrence rates for heart failure patients
Heart monitoring helps identify risks in heart failure patients
This randomized controlled trial of 711 ambulatory patients with symptomatic heart failure found no significant difference in arrhythmia occ…
New data shows that specific heart rhythm issues detected by implants can signal a higher risk of hospital stays and medical interventions.
Magnesium sulfate did not significantly reduce postoperative atrial fibrillation incidence in cardiac surgery patients
Trial shows magnesium sulfate does not prevent heart rhythm issues
This randomized clinical trial of 265 adult patients undergoing coronary artery bypass grafting or valvular surgery found that magnesium sul…
A clinical trial found that giving patients magnesium during heart surgery did not reduce the risk of developing a common irregular heartbea…
From Other Specialties
Virtual reality exercise training improves walking capacity and reduces fall risk in older adults
Virtual reality exercise boosts walking and cuts fall risk in older adults
This meta-analysis of 2927 healthy older adults found that virtual reality (VR) based exercise training significantly improved six-minute wa…
Older adults who did VR-based exercise walked farther, moved faster, and felt less afraid of falling, a new analysis of 2,927 people finds.
Social isolation and loneliness are associated with increased frailty risk in general populations
Social isolation and loneliness increase the risk of physical frailty
This meta-analysis of 78,769 individuals found that social isolation and loneliness significantly increase the risk of frailty. Specifically…
Feeling alone or isolated can lead to a higher risk of frailty, making it harder for older adults to stay strong and independent.
Sarcopenia is associated with 2.30 higher odds of cognitive impairment in Latin American adults
Sarcopenia Linked to Higher Risk of Cognitive Impairment
This systematic review and meta-analysis of 8 studies involving 13,395 community-dwelling adults in Latin America found that sarcopenia is s…
A large review of data from Latin America shows that muscle loss in older adults is linked to a much higher risk of cognitive impairment.
Esketamine reduces 3-month postpartum depression incidence from 20.89% to 11.59% in primiparae
Trial shows esketamine reduces postpartum depression risk in new mothers
This randomized controlled trial of 322 primiparae found that a single dose of esketamine significantly reduced the incidence of postpartum …
A clinical trial suggests that a single dose of esketamine during C-section surgery may lower the risk of developing postpartum depression.